Brief: uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
19/12/2023 13:26
Dec 19 (Reuters) - Uniqure NV UQ1.F :
* UNIQURE ANNOUNCES UPDATE ON PHASE I/II CLINICAL TRIALS OF
AMT-130 GENE THERAPY FOR THE TREATMENT OF HUNTINGTON’S DISEASE
Source text for Eikon: ID:nGNECb2TG
Further company coverage: UQ1.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal